期刊文献+

乳腺癌患者术后服用他莫昔芬引发子宫内膜病变的临床研究 被引量:7

下载PDF
导出
摘要 目的分析乳腺癌术后患者服用他莫昔芬与子宫内膜病变的关系,为此类患者在用药过程随访和治疗子宫病变提供临床依据。方法回顾性分析2001年1月-2012年12月于唐山市工人医院妇科住院的乳腺癌术后引发子宫内膜病变患者共25例,根据患者是否服用他莫昔芬分为他莫昔芬(TAM)组(17例)和非他莫昔芬(NON—TAM)组(8例),探讨其与子宫内膜病变的关系。结果TAM组与NON—TAM组子宫内膜厚度之间、两组中绝经前患者子宫内膜厚度之间、绝经后患者子宫内膜厚度差异均有显著性(P〈0.05)。结论乳腺癌患者长期使用他莫昔芬会引起子宫内膜异常,对乳腺癌术后服用他莫昔芬患者应于服药前和服药过程中监测子宫内膜改变。
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2013年第30期106-108,共3页 China Journal of Modern Medicine
  • 相关文献

参考文献13

  • 1SMIGAL C, A JEMAL, E WARD, et al. Trends in breast cancerby race and ethnicity: update 2006[J]. CA: A Cancer Journal ForClinicians, 2006, 56(3): 168-183.
  • 2YOULDEN DR, SM CRAMB,NAM DUNN, et al. The descrip-tive epidemiology of female breast cancer: an international com-parison of screening, incidence, survival and mortality [J]. CancerEpidemiology, 2012, 36(3): 237-248.
  • 3MACGREGOR JI, VC JORDAN. Basic guide to the mechanismsof antiestrogen action[J]. Pharmacol Rev, 1998, 50(2): 151-196.
  • 4PASQUAUNI JR, C SUMIDA, N GIAMBIAGI. Pharmacodynamicand biological effects of anti-estrogens in different models [J]. JSteroid Biochem, 1988, 31(4B): 613-643.
  • 5Systemic treatment of early breast cancer by hormonal, cytotoxic,or immune therapy. 133 randomised trials involving 31,000 re-currences and 24,000 deaths among 75,000 women. Early BreastCancer Trialists' Collaborative Group. Lancet, 1992, 339 (8784):1-15.
  • 6HUIART L, FERDYNUS C, GIORGI R. Tamoxifen therapy forpatients with breast cancer[J]. Lancet, 2013, 381(9883): 2077.
  • 7CLARKE M. Meta-analyses of adjuvant therapies for women withearly breast cancer: the Early Breast Cancer Trialists' Collabora-tive Group overview. Annals of Oncology, 2006,17 (suppl 10):x59-x62.
  • 8STEWART HJ, FORREST AP, EVERINGTON D, et al. Ran-domised comparison of 5 years of adjuvant tamoxifen with con-tinuous therapy for operable breast cancer[J]. The Scottish CancerTrials Breast Group. Br J Cancer, 1996, 74(2): 297-299.
  • 9DAVIES C, GODWIN J, GRAY R, et al. Relevance of breastcancer hormone receptors and other factors to the efficacy of ad-juvant tamoxifen: patient-level meta-analysis of randomised trials[J]. Lancet, 2011, 378(9793): 771-784.
  • 10KILLACKEY MA, TB HAKES, VK PIERCE. Endometrial ade-nocarcinoma in breast cancer patients receiving antiestrogens [J].Cancer Treat Rep, 1985, 69(2): 237-238.

同被引文献77

  • 1邓姗,郎景和.左炔诺孕酮宫内缓释系统的临床功用及相关基础研究[J].国外医学(妇产科学分册),2004,31(5):285-288. 被引量:148
  • 2杨保军,邢凤玲,冯力民,张华,孙海梅.它莫西芬对子宫内膜血管内皮生长因子表达的影响[J].首都医科大学学报,2007,28(3):412-414. 被引量:3
  • 3Allred DC, Anderson S J, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24[J]. J Clin Oncol, 2012, 30(12): 1268- 1273.
  • 4Van DE, Velde C J, Verma S, et al. Switching from tamoxi- fen to aromatase inhibitors for adjuvant endocrine therapyin postmenopausal patients with early breast cancer[J]. Can- cer Treat Rev, 2010, 36(1): 54-62.
  • 5Youlden DR, Cramb SM, Dunn NAM, et al. The descriptive epidemiology of female breast cancer: an international com- parison of screening, incidence, survival and mortality[J]. Cancer Epidemiology, 2012, 36(3): 237-248.
  • 6Ma L, Li G, Zhu H, et al. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by si- multaneously dysregulating hypoxia-inducible factor-1 and -2 [J]. Cancer Lett, 2014, 355(1): 96-105. doi: 10. 1016/j. canlet. 2014.09.011.
  • 7Jordan VC. Tamoxifen as the first targeted long-term ad- juvant therapy for breast cancer [J], Endocr Relat Cancer, 2014, 21(3): R235-R246. doi: 10. 1530/ERC-14-0092.
  • 8Wang Y, Lei R, Zhuang X, et al. DLC 1-dependent para- thyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis [J]. J Clin Invest, 2014, 124(4): 1646-1659. doi: 10. 1172/JCI71812.
  • 9Mokkapati S, Niopek K, Huang L, et al/3-catenin activa- tion in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma [J]. Cancer Res, 2014, 74(16): 4515-4525. doi: 10. 1158/0008-5472. CAN-13-3275.
  • 10Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro [J]. Int J Mol Sci, 2014, 15(3): 4019-4030. doi: 10. 3390/ijms15034019.

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部